We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Bladder Cancer

Journal Scan / Research · July 18, 2022

BCG Therapy Downregulates HLA-I on Malignant Cells to Subvert Antitumor Immune Responses in Bladder Cancer

The Journal of Clinical Investigation


Additional Info

The Journal of Clinical Investigation
BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer
J. Clin. Invest. 2022 Jun 15;132(12)xx, M Rouanne, J Adam, C Radulescu, D Letourneur, D Bredel, S Mouraud, AG Goubet, M Leduc, N Chen, TZ Tan, N Signolle, A Bigorgne, M Dussiot, L Tselikas, S Susini, FX Danlos, AK Schneider, R Chabanon, S Vacher, I Bièche, T Lebret, Y Allory, JC Soria, N Arpaia, G Kroemer, O Kepp, JP Thiery, L Zitvogel, A Marabelle

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading